Abstract |
Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD demonstrated responses in patients with B-cell non-Hodgkin lymphoma (NHL). This phase II trial evaluated response rate (RR) and tolerability of DD in this population. Patients were stratified into two arms: those with NHL expressing > or =20% IL-2R (IL-2R+) or <20% IL-2R (IL-2R-). DD was dosed at 18 microg/kg/day for 5 days every 21 days. Corticosteroid pre-medication was not allowed. Thirty-five patients of a planned 77 accrued due to closure for slow accrual. This report is on 29 patients (18 males) with indolent B-cell NHL (11 IL-2R+ and 18 IL-2R-). Histologic subtypes included small lymphocytic (SLL) (8 patients) and follicular grade I/II lymphoma (21 patients). Patients received a median of three prior regimens, including rituximab in 76%. Three partial responses were observed (RR 10%). The RR for the IL-2R- and IL-2R+ patients was 11% and 9%, respectively. Of 8 patients with SLL, 2 responded. Toxicities were generally grade I - II and transient but 1 patient experienced a fatal thrombo- embolism. Therapy with DD is tolerable and modest efficacy was observed in SLL subtype. Measured IL-2R status did not correlate with efficacy.
|
Authors | Timothy M Kuzel, Shuli Li, John Eklund, Francine Foss, Randy Gascoyne, Neil Abramson, John F Schwerkoske, Edie Weller, Sandra J Horning |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 48
Issue 12
Pg. 2397-402
(Dec 2007)
ISSN: 1042-8194 [Print] United States |
PMID | 17943599
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Diphtheria Toxin
- Interleukin-2
- Receptors, Interleukin-2
- Recombinant Fusion Proteins
- denileukin diftitox
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Diphtheria Toxin
(adverse effects, therapeutic use)
- Female
- Humans
- Interleukin-2
(adverse effects, therapeutic use)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Receptors, Interleukin-2
(analysis)
- Recombinant Fusion Proteins
(adverse effects, therapeutic use)
|